Seres Therapeutics' SER-155 achieves 80% immunosuppressive-free response in irEC trial
MCRB sits 64% above its 52-week low of $5.31.
Summary
Seres Therapeutics announced positive clinical data for its drug candidate SER-155, achieving an 80% immunosuppressive-free clinical response in patients with immune checkpoint inhibitor-related enterocolitis. 12 of 15 patients met the primary endpoint, and the drug was well tolerated with no serious adverse events. This promising data follows the company's Q1 net loss and going concern warning in May, which underscored an urgent need for funding. Strong clinical results like these are crucial for Seres Therapeutics to attract further investment and advance its pipeline, especially after securing a $25 million payment from Nestlé Health Science in June. The study supports continued development of SER-155.
At the time of this announcement, MCRB was trading at $8.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $78.8M. The 52-week trading range was $5.31 to $29.98. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.